Skip to content

Impact of a Proactive Strategy of General Practitioners on CRC Screening

Impact of a Proactive Strategy of General Practitioners on CRC Screening: a Registry-based Cluster-based Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06664567
Acronym
DECORE
Enrollment
26260
Registered
2024-10-29
Start date
2026-01-01
Completion date
2028-01-31
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

colorectal cancer screening, general practitioner, social health inequalities

Brief summary

In this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners (GP) who will systematically provide screening kits of colorectal cancer (CRC) to all patients of even age (50, 52, 54...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit.

Detailed description

Colorectal cancer is one of the leading causes of cancer and death in France in both men and women. The generalized screening rate is about 30% in France, far from the expected 65%, despite the fact that screening is free and a letter of invitation is sent to the individual's home, and despite the financial incentives provided to the practitioner. Different studies have looked for the causes of non-implementation by the individual: negligence, dirty; forgetfulness, and the practitioner: organizational problem, communication problem. A few intervention studies have been carried out with little success: sending the invitation to the individual's home, sending a letter of reminder, sending a letter of general information on screening to the practitioner, sending the list of patients who have not taken the test to the practitioner allows for a few percent improvement in screening. In this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners who will systematically provide screening kits of colorectal cancer to all patients of even age (50, 52, 54 years...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit. The screening rate will be calculated for each arm at the end of the 2-year study with data from the health insurance.

Interventions

BEHAVIORALColorectal cancer screening test

delivery of colorectal cancer screening test by GP

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

\- medical practices in Aquitaine region and their visiting patients eligible for colorectal cancer screening individuals aged between 50 and 74 years at intermediate risk of colorectal cancer).

Exclusion criteria

* medical practices with less than five individual eligible for colorectal cancer screening. * visiting patients aged less than 50 years or more than 74 years or at high or very high risk of colorectal cancer.

Design outcomes

Primary

MeasureTime frameDescription
Participation rate in CRC screening2 years after the start of protocolThe primary endpoint of this trial is the rate of participation rate in CRC screening in the eligible patient population grouped with or without intervention. This criterion will be measured by retrospective analysis of retrospective analysis of National Health Data System data.

Secondary

MeasureTime frameDescription
Positive test results2 years after the start of protocolRate of patients with positive test results
Positive test at an early stage2 years after the start of protocolrate of patients tested positive at an early stage
Positive test at a last stage2 years after the start of protocolrate of patients testing positive at a late stage

Contacts

Primary ContactChristele BLANC-BISSON, Dr
christele.blanc-bisson@u-bordeaux.fr05 56 65 55 00
Backup ContactPierre POULIZAC
pierre.poulizac@chu-bordeaux.fr05 57 82 08 49

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026